联合治疗神经精神型毒蕈中毒46例临床分析  

Clinical Analysis of Joint Treatment for 46 Patients with Neuropsychiatric Type of Mushroom Poisoning

作　　者：刘林东 杨吉林[2] 董丽宏[2] 符琛 巴瑞琼 

机构地区：[1]曲靖市第一人民医院急诊科,云南曲靖655000 [2]昆明医学院第一附属医院重症医学科,云南昆明650032 [3]曲靖市第一人民医院神经内科,云南曲靖655000

出　　处：《昆明医学院学报》2012年第3期115-117,共3页Journal of Kunming Medical College

摘　　要：目的探讨急性神经精神型毒蕈中毒的临床特点及其治疗方法,以提高急救成功率及减少并发症.方法回顾性分析曲靖市第一人民医院急诊科2006年6月至2011年9月收治的76例成年人急性毒蕈中毒的临床资料,随机选取46例急性神经精神型毒蕈中毒患者作为联合治疗组,30例患者作为传统治疗组:传统治疗组病例在常规治疗的基础上采用地西泮和奋乃静控制精神症状治疗,联合治疗组46病例在常规治疗的基础上联合运用氟哌啶醇加氢溴酸东莨菪碱抗精神障碍治疗.结果随访76例,随访时间6个月～5 a,随访期内未发生严重并发症,无死亡病例,联合治疗组总优良率为96%,传统治疗组总优良率为60%,联合治疗组与传统治疗组疗效比较统计学有显著性差异(P<0.05).结论常规治疗的基础上联合运用氟哌啶醇加氢溴酸东莨菪碱治疗神经精神型毒蕈中毒能明显缩短病程,神经精神症状恢复快,疗效肯定,临床上有很好的推广应用价值.Objective To investigate the clinical characteristics and treatments of acute neuropsychiatric mushroom poisoning in order to improve the success rate of first aid and reduce complications.Methods The clinical data were retrospectively analyzed for 76 adult patients with acute mushroom poisoningn for the past five years in my hospital.46 patients were randomly selected and assigned to the joint treatment group and 30 patients to the conventional treatment group.The conventional and anti-mental disorder treatments with haloperidol plus scopolamine hydrobromide were used for the joint treatment group,while diazepam or perphenazine was used for the conventional treatment group.Results 76 cases were followed up for 6 months up to 5 years.There were no serious complications or deaths in the follow-up period.The good or excellent rate was 96% in the joint treatment group and 60% in the conventional groups.The difference in treatment effect between the two groups was statistically significant(P<0.05).Conclusion The combination of conventional treatment with the joint use of haloperidol plus scopolamine hydrobromide for neuropsychiatric mushroom poisoning can significantly shorten the course of neuropsychiatric symptoms and fasten recovery,and has good value of clinical application.

关 键 词：神经精神型 毒蕈中毒 氟哌啶醇 氢溴酸东莨菪碱 

分 类 号：R59[医药卫生—内科学]